User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

Primary tabs

download
  • Open access
  • PDF
  • 702.67 K
Walter, Roland B. Othus, Megan Burnett, Alan K. Löwenberg, Bob Kantarjian, Hagop M. Vekemans, Marie-Christiane [UCL] Estey, Elihu H.

Therapeutic resistance remains the principal problem in acute myeloid leukemia (AML). We used area under receiver-operating characteristic curves (AUCs) to quantify our ability to predict therapeutic resistance in individual patients, where AUC=1.0 denotes perfect prediction and AUC=0.5 denotes a coin flip, using data from 4601 patients with newly diagnosed AML given induction therapy with 3+7 or more intense standard regimens in UK Medical Research Council/National Cancer Research Institute, Dutch-Belgian Cooperative Trial Group for Hematology/Oncology/Swiss Group for Clinical Cancer Research, US cooperative group SWOG and MD Anderson Cancer Center studies. Age, performance status, white blood cell count, secondary disease, cytogenetic risk and FLT3-ITD/NPM1 mutation status were each independently associated with failure to achieve complete remission despite no early death ('primary refractoriness'). However, the AUC of a bootstrap-corrected multivariable model predicting this outcome was only 0.78, indicating only fair predictive ability. Removal of FLT3-ITD and NPM1 information only slightly decreased the AUC (0.76). Prediction of resistance, defined as primary refractoriness or short relapse-free survival, was even more difficult. Our limited ability to forecast resistance based on routinely available pretreatment covariates provides a rationale for continued randomization between standard and new therapies and supports further examination of genetic and posttreatment data to optimize resistance prediction in AML.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès mixte
Publication date 2015
Language Anglais
Journal information "Leukemia" - Vol. 29, no. 2, p. 312-320 (2015)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) London)
issn 0887-6924
e-issn 1476-5551
Publication status Publié
Affiliations UCL - (SLuc) Service d'hématologie
UCL - SSS/IREC/SLUC - Pôle St.-Luc
Keywords Acute myeloid leukemia ; Area under the receiver operator characteristic curve ; Prediction ; Therapeutic resistance
Links
  1. Estey Elihu, Döhner Hartmut, Acute myeloid leukaemia, 10.1016/s0140-6736(06)69780-8
  2. Dohner H., Estey E. H., Amadori S., Appelbaum F. R., Buchner T., Burnett A. K., Dombret H., Fenaux P., Grimwade D., Larson R. A., Lo-Coco F., Naoe T., Niederwieser D., Ossenkoppele G. J., Sanz M. A., Sierra J., Tallman M. S., Lowenberg B., Bloomfield C. D., Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, 10.1182/blood-2009-07-235358
  3. Ferrara Felicetto, Schiffer Charles A, Acute myeloid leukaemia in adults, 10.1016/s0140-6736(12)61727-9
  4. Burnett Alan K., Russell Nigel H., Hills Robert K., Hunter Ann E., Kjeldsen Lars, Yin John, Gibson Brenda E.S., Wheatley Keith, Milligan Donald, Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial, 10.1200/jco.2012.47.4874
  5. Kayser S., Zucknick M., Dohner K., Krauter J., Kohne C.-H., Horst H. A., Held G., von Lilienfeld-Toal M., Wilhelm S., Rummel M., Germing U., Gotze K., Nachbaur D., Schlegelberger B., Gohring G., Spath D., Morlok C., Teleanu V., Ganser A., Dohner H., Schlenk R. F., , Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies, 10.1182/blood-2011-07-367508
  6. Walter Roland B., Othus Megan, Borthakur Gautam, Ravandi Farhad, Cortes Jorge E., Pierce Sherry A., Appelbaum Frederick R., Kantarjian Hagop A., Estey Elihu H., Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment, 10.1200/jco.2011.35.7525
  7. Cheson Bruce D., Bennett John M., Kopecky Kenneth J., Büchner Thomas, Willman Cheryl L., Estey Elihu H., Schiffer Charles A., Doehner Hartmut, Tallman Martin S., Lister T. Andrew, Lo-Coco Francesco, Willemze Roel, Biondi Andrea, Hiddemann Wolfgang, Larson Richard A., Löwenberg Bob, Sanz Miguel A., Head David R., Ohno Ryuzo, Bloomfield Clara D., Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, 10.1200/jco.2003.04.036
  8. Kaplan E. L., Meier Paul, Nonparametric Estimation from Incomplete Observations, 10.1080/01621459.1958.10501452
  9. Muller Matthew P., Tomlinson George, Marrie Thomas J., Tang Patrick, McGeer Allison, Low Donald E., Detsky Allan S., Gold Wayne L., Can Routine Laboratory Tests Discriminate between Severe Acute Respiratory Syndrome and Other Causes of Community‐Acquired Pneumonia?, 10.1086/428577
  10. Ishihara Ryu, Yamada Takuya, Iishi Hiroyasu, Kato Motohiko, Yamamoto Shunsuke, Yamamoto Sachiko, Masuda Eriko, Tatsumi Koichi, Takeuchi Yoji, Higashino Koji, Uedo Noriya, Tatsuta Masaharu, Ishiguro Shingo, Quantitative analysis of the color change after iodine staining for diagnosing esophageal high-grade intraepithelial neoplasia and invasive cancer, 10.1016/j.gie.2008.04.052
  11. Roelen C. A., van Rhenen W., Groothoff J. W., van der Klink J. J., Bultmann U., Heymans M. W., The development and validation of two prediction models to identify employees at risk of high sickness absence, 10.1093/eurpub/cks036
  12. HARRELL FRANK E., LEE KERRY L., MARK DANIEL B., MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, 10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
  13. Harrell Frank E., Margolis Peter A., Gove Sandy, Mason Karen E., Mulholland E. Kim, Lehmann Deborah, Muhe Lulu, Gatchalian Salvacion, Eichenwald Heinz F., , Development of a clinical prediction model for an ordinal outcome: the World Health Organization Multicentre Study of Clinical Signs and Etiological Agents of Pneumonia, Sepsis and Meningitis in Young Infants, 10.1002/(sici)1097-0258(19980430)17:8<909::aid-sim753>3.0.co;2-o
  14. Othus M, Blood, 122, 3925 (2013)
  15. Appelbaum F. R., Age and acute myeloid leukemia, 10.1182/blood-2005-09-3724
  16. Yanada M., Garcia-Manero G., Borthakur G., Ravandi F., Kantarjian H., Estey E., Relapse and death during first remission in acute myeloid leukemia, 10.3324/haematol.12366
  17. Krug Utz, Röllig Christoph, Koschmieder Anja, Heinecke Achim, Sauerland Maria Cristina, Schaich Markus, Thiede Christian, Kramer Michael, Braess Jan, Spiekermann Karsten, Haferlach Torsten, Haferlach Claudia, Koschmieder Steffen, Rohde Christian, Serve Hubert, Wörmann Bernhard, Hiddemann Wolfgang, Ehninger Gerhard, Berdel Wolfgang E, Büchner Thomas, Müller-Tidow Carsten, Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes, 10.1016/s0140-6736(10)62105-8
  18. Taskesen E., Bullinger L., Corbacioglu A., Sanders M. A., Erpelinck C. A. J., Wouters B. J., van der Poel-van de Luytgaarde S. C., Damm F., Krauter J., Ganser A., Schlenk R. F., Lowenberg B., Delwel R., Dohner H., Valk P. J. M., Dohner K., Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity, 10.1182/blood-2010-09-307280
  19. Ley Timothy J., Ding Li, Walter Matthew J., McLellan Michael D., Lamprecht Tamara, Larson David E., Kandoth Cyriac, Payton Jacqueline E., Baty Jack, Welch John, Harris Christopher C., Lichti Cheryl F., Townsend R. Reid, Fulton Robert S., Dooling David J., Koboldt Daniel C., Schmidt Heather, Zhang Qunyuan, Osborne John R., Lin Ling, O'Laughlin Michelle, McMichael Joshua F., Delehaunty Kim D., McGrath Sean D., Fulton Lucinda A., Magrini Vincent J., Vickery Tammi L., Hundal Jasreet, Cook Lisa L., Conyers Joshua J., Swift Gary W., Reed Jerry P., Alldredge Patricia A., Wylie Todd, Walker Jason, Kalicki Joelle, Watson Mark A., Heath Sharon, Shannon William D., Varghese Nobish, Nagarajan Rakesh, Westervelt Peter, Tomasson Michael H., Link Daniel C., Graubert Timothy A., DiPersio John F., Mardis Elaine R., Wilson Richard K., DNMT3AMutations in Acute Myeloid Leukemia, 10.1056/nejmoa1005143
  20. Paschka Peter, Schlenk Richard F., Gaidzik Verena I., Habdank Marianne, Krönke Jan, Bullinger Lars, Späth Daniela, Kayser Sabine, Zucknick Manuela, Götze Katharina, Horst Heinz-A., Germing Ulrich, Döhner Hartmut, Döhner Konstanze, IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication, 10.1200/jco.2010.28.3762
  21. Metzeler K. H., Becker H., Maharry K., Radmacher M. D., Kohlschmidt J., Mrozek K., Nicolet D., Whitman S. P., Wu Y.-Z., Schwind S., Powell B. L., Carter T. H., Wetzler M., Moore J. O., Kolitz J. E., Baer M. R., Carroll A. J., Larson R. A., Caligiuri M. A., Marcucci G., Bloomfield C. D., ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category, 10.1182/blood-2011-08-368225
  22. Rucker F. G., Schlenk R. F., Bullinger L., Kayser S., Teleanu V., Kett H., Habdank M., Kugler C.-M., Holzmann K., Gaidzik V. I., Paschka P., Held G., von Lilienfeld-Toal M., Lubbert M., Frohling S., Zenz T., Krauter J., Schlegelberger B., Ganser A., Lichter P., Dohner K., Dohner H., TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome, 10.1182/blood-2011-08-375758
  23. Patel Jay P., Gönen Mithat, Figueroa Maria E., Fernandez Hugo, Sun Zhuoxin, Racevskis Janis, Van Vlierberghe Pieter, Dolgalev Igor, Thomas Sabrena, Aminova Olga, Huberman Kety, Cheng Janice, Viale Agnes, Socci Nicholas D., Heguy Adriana, Cherry Athena, Vance Gail, Higgins Rodney R., Ketterling Rhett P., Gallagher Robert E., Litzow Mark, van den Brink Marcel R.M., Lazarus Hillard M., Rowe Jacob M., Luger Selina, Ferrando Adolfo, Paietta Elisabeth, Tallman Martin S., Melnick Ari, Abdel-Wahab Omar, Levine Ross L., Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia, 10.1056/nejmoa1112304
  24. Walter Matthew J., Shen Dong, Ding Li, Shao Jin, Koboldt Daniel C., Chen Ken, Larson David E., McLellan Michael D., Dooling David, Abbott Rachel, Fulton Robert, Magrini Vincent, Schmidt Heather, Kalicki-Veizer Joelle, O'Laughlin Michelle, Fan Xian, Grillot Marcus, Witowski Sarah, Heath Sharon, Frater John L., Eades William, Tomasson Michael, Westervelt Peter, DiPersio John F., Link Daniel C., Mardis Elaine R., Ley Timothy J., Wilson Richard K., Graubert Timothy A., Clonal Architecture of Secondary Acute Myeloid Leukemia, 10.1056/nejmoa1106968
  25. Haferlach T, Haematologica, 89, 408 (2004)
  26. Elliott M. A., Litzow M. R., Letendre L. L., Wolf R. C., Hanson C. A., Tefferi A., Tallman M. S., Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival, 10.1182/blood-2007-07-104091
  27. Loken M. R., Alonzo T. A., Pardo L., Gerbing R. B., Raimondi S. C., Hirsch B. A., Ho P. A., Franklin J., Cooper T. M., Gamis A. S., Meshinchi S., Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group, 10.1182/blood-2012-02-408336
  28. Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A, Vey N, Casasnovas O, Witz F, Béné M C, Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study, 10.1038/leu.2008.296
  29. Freeman Sylvie D., Virgo Paul, Couzens Steve, Grimwade David, Russell Nigel, Hills Robert K., Burnett Alan K., Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia, 10.1200/jco.2013.49.1753
  30. Terwijn Monique, van Putten Wim L.J., Kelder Angèle, van der Velden Vincent H.J., Brooimans Rik A., Pabst Thomas, Maertens Johan, Boeckx Nancy, de Greef Georgine E., Valk Peter J.M., Preijers Frank W.M.B., Huijgens Peter C., Dräger Angelika M., Schanz Urs, Jongen-Lavrecic Mojca, Biemond Bart J., Passweg Jakob R., van Gelder Michel, Wijermans Pierre, Graux Carlos, Bargetzi Mario, Legdeur Marie-Cecile, Kuball Jurgen, de Weerdt Okke, Chalandon Yves, Hess Urs, Verdonck Leo F., Gratama Jan W., Oussoren Yvonne J.M., Scholten Willemijn J., Slomp Jennita, Snel Alexander N., Vekemans Marie-Christiane, Löwenberg Bob, Ossenkoppele Gert J., Schuurhuis Gerrit J., High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study, 10.1200/jco.2012.45.9628
  31. Grimwade D., Hills R. K., Moorman A. V., Walker H., Chatters S., Goldstone A. H., Wheatley K., Harrison C. J., Burnett A. K., , Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, 10.1182/blood-2009-11-254441
  32. Breems Dimitri A., Van Putten Wim L.J., De Greef Georgine E., Van Zelderen-Bhola Shama L., Gerssen-Schoorl Klasien B.J., Mellink Clemens H.M., Nieuwint Aggie, Jotterand Martine, Hagemeijer Anne, Beverloo H. Berna, Löwenberg Bob, Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype, 10.1200/jco.2008.16.0259
Bibliographic reference Walter, Roland B. ; Othus, Megan ; Burnett, Alan K. ; Löwenberg, Bob ; Kantarjian, Hagop M. ; et. al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. In: Leukemia, Vol. 29, no. 2, p. 312-320 (2015)
Permanent URL http://hdl.handle.net/2078.1/164354